Why Sol-Gel Technologies Ltd.’s (SLGL) Stock Is Down 5.90%
As of Wednesday, July 08, Sol-Gel Technologies Ltd.’s SLGL share price has dipped by 5.90%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Commentary & Analysis
Why Sol-Gel Technologies Ltd.’s (SLGL) Stock Is Up 9.66%
As of Friday, June 26, Sol-Gel Technologies Ltd.’s SLGL share price has surged by 9.66%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Sol-Gel Technologies Ltd.’s (SLGL) Stock Is Up 8.07%
As of Wednesday, June 24, Sol-Gel Technologies Ltd.’s SLGL share price has surged by 8.07%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Sol-Gel Technologies Ltd.’s (SLGL) Stock Is Down 6.44%
As of Tuesday, June 09, Sol-Gel Technologies Ltd.’s SLGL share price has dipped by 6.44%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Sol-Gel Technologies Ltd.’s (SLGL) Stock Is Down 6.06%
As of Monday, May 18, Sol-Gel Technologies Ltd.’s SLGL share price has dipped by 6.06%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | SLGL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $270.4 | $579.1 | 31% |
|
| Shares Out (Mil) | 2.8 | 43.0 | 9% |
|
| Institutional Ownership | 18.4% | 84.3% | 10% |
|
| Float (Mil) | 0.5 | 46.8 | 1% |
|
| Beta | 1.13 | 0.62 | 67% |
|
| Avg Daily Volume (000s) | 51 | 285 | 28% |
|
| Price Change (52-week) |
562.9% | 63.8% | 100% |
|
| Growth | SLGL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 17.1% | 6.7% | 77% |
|
| Net Income (5yr) | 26.9% | (1.4%) | 82% |
|
| EPS (5yr) | 29.9% | 14.9% | 81 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (35.6%) | (14.9%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 4 | 4 | |
| Current EPS | ($2.310) | ($8.318) | ($8.145) | |
| Month Ago EPS | ($3.330) | ($8.525) | ($9.203) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($1.810) | ($6.810) | na | |
| Year/Year Chg | 115.5% | 278.3% | (2.2%) | |
| Financials | SLGL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $19 | $272 | 13% |
|
| Net Income (TTM) (Mil) | ($6) | ($11) | 33% |
|
| EPS (TTM) | ($2.199) | ($0.500) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | na | ($6) | na |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $7 | 15% |
|
| Enterprise Value (Q1) (Mil) | $94 | $522 | 21% |
|
| Valuation | SLGL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.10 | 2.73 | 90% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | SLGL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 9.3% | 65.9% | 9% |
|
| Net Margin | (5.7%) | 0.7% | 24% |
|
| ROA | (16.3%) | (24.6%) | 22% |
|
| ROE | (19.9%) | (19.7%) | 23% |
|
| Liabilities to Assets | 23.8% | 35.5% | 16% |
|
| F-Score | 5 | 3 | 51% |
|
Sol-Gel Technologies Ltd. did not pass any screens on 7/31/2026.
